Recomendaciones de la Sociedad Española de Reumatología sobre osteoporosis

Azagra, 2014, Changing trends in the epidemiology of hip fracture in Spain, Osteoporos Int., 25, 1267, 10.1007/s00198-013-2586-0 Hernlund, 2013, Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA), Arch Osteoporos., 8, 136, 10.1007/s11657-013-0136-1 Kanis, 2013, SCOPE: A scorecard for osteoporosis in Europe, Arch Osteoporos., 8, 144, 10.1007/s11657-013-0144-1 Kanis, 2014, The osteoporosis treatment gap, J Bone Miner Res., 29, 1926, 10.1002/jbmr.2301 Perez Edo, 2011, 2011 Up-date of the consensus statement of the Spanish Society of Rheumatology on osteoporosis, Reumatol Clin., 7, 357 2001, Osteoporosis prevention, diagnosis, and therapy, JAMA, 285, 785, 10.1001/jama.285.6.785 Kanis, 2001, The burden of osteoporotic fractures: A method for setting intervention thresholds, Osteoporos Int., 12, 417, 10.1007/s001980170112 1994, Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group, World Health Organ Tech Rep Ser., 843, 1 Kanis, 2007 Siris, 2014, Osteoporos Int, 25, 1439, 10.1007/s00198-014-2655-z Black, 2016, Clinical practice. Postmenopausal osteoporosis, N Engl J Med., 374, 254, 10.1056/NEJMcp1513724 Roux, 2017, Imminent fracture risk, Osteoporos Int., 28, 1765, 10.1007/s00198-017-3976-5 Johansson, 2017, Imminent risk of fracture after fracture, Osteoporos Int., 28, 775, 10.1007/s00198-016-3868-0 Kanis, 2007, The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women, Osteoporos Int., 18, 1033, 10.1007/s00198-007-0343-y Cummings, 1995, Risk factors for hip fracture in white women, N Engl J Med., 332, 767, 10.1056/NEJM199503233321202 Rubin, 2013, Risk assessment tools to identify women with increased risk of osteoporotic fracture: Complexity or simplicity? A systematic review, J Bone Miner Res., 28, 1701, 10.1002/jbmr.1956 Marques, 2015, The accuracy of osteoporotic fracture risk prediction tools: A systematic review and meta-analysis, 74, 1958 Kanis, 2011, Interpretation and use of FRAX in clinical practice, Osteoporos Int., 22, 2395, 10.1007/s00198-011-1713-z Tebé C, Espallargues M, Estrada MD, Kotzeva A, del Río LM, di Gregorio S. Validación del modelo predictivo de fractura osteoporótica FRAX. Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad. Agència d’Informació, Avaluació i Qualitat en Salut; 2011. Informes de Evaluación de Tecnologías Sanitarias, AIAQS núm. 2010/01. Azagra, 2012, FRAX® tool, the WHO algorithm to predict osteoporotic fractures: The first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort, BMC Musculoskelet Disord., 13, 204, 10.1186/1471-2474-13-204 Gonzalez-Macias, 2012, Probability of fractures predicted by FRAX® and observed incidence in the Spanish ECOSAP Study cohort, Bone., 50, 373, 10.1016/j.bone.2011.11.006 Azagra, 2015, Umbrales de FRAX para determinar personas con alto y bajo riesgo de fractura osteoporótica en población femenina española, Med Clin (Barc)., 144, 1, 10.1016/j.medcli.2013.11.014 Azagra, 2016, Fracture experience among participants from the FROCAT study: What thresholding is appropriate using the FRAX tool?, Maturitas., 83, 65, 10.1016/j.maturitas.2015.10.002 Schousboe, 2013, Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Bone Densitometry, J Clin Densitom., 16, 455, 10.1016/j.jocd.2013.08.004 Marshall, 1996, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, BMJ., 312, 1254, 10.1136/bmj.312.7041.1254 Wainwright, 2005, Hip fracture in women without osteoporosis, J Clin Endocrinol Metab., 90, 2787, 10.1210/jc.2004-1568 Lespessailles, 2017, Low-trauma fractures without osteoporosis, Osteoporos Int., 28, 1771, 10.1007/s00198-017-3921-7 Cummings, 2002, Clinical use of bone densitometry: Scientific review, JAMA., 288, 1889, 10.1001/jama.288.15.1889 Lewiecki, 2004, Official positions of the international society for clinical densitometry, J Clin Endocrinol Metab., 89, 3651, 10.1210/jc.2004-0124 Cosman, 2014, Clinician's guide to prevention and treatment of osteoporosis, Osteoporos Int., 25, 2359, 10.1007/s00198-014-2794-2 Papaioannou, 2010, 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary, CMAJ., 182, 1864, 10.1503/cmaj.100771 Bouman, 2015, Predictive value of a multi-biomarker disease activity score for successful dose reduction of TNF inhibitors in rheumatoid arthritis: Results of the dress study, Ann Rheum Dis., 74, 973, 10.1136/annrheumdis-2015-eular.2972 Gomez-Vaquero, 2013, Assessment of a set of FRAX®-based criteria for the indication of bone densitometry in Spanish postmenopausal women, Med Clin (Barc)., 140, 439 Azagra, 2015, [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population], Med Clin (Barc)., 144, 1, 10.1016/j.medcli.2013.11.014 Hadji, 2017, Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG, J Bone Oncol., 7, 1, 10.1016/j.jbo.2017.03.001 Buckley, 2017, 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis, Arthritis Rheumatol., 69, 1521, 10.1002/art.40137 Cianferotti, 2017, The prevention of fragility fractures in patients with non-metastatic prostate cancer: A position statement by the international osteoporosis foundation, Oncotarget., 8, 75646, 10.18632/oncotarget.17980 Silva, 2017, Trabecular bone score: A new DXA-derived measurement for fracture risk assessment, Endocrinol Metab Clin North Am., 46, 153, 10.1016/j.ecl.2016.09.005 Del Rio, 2013, Is bone microarchitecture status of the lumbar spine assessed by TBS related to femoral neck fracture? A Spanish case-control study, Osteoporos Int., 24, 991, 10.1007/s00198-012-2008-8 Martineau, 2017, Trabecular bone score (TBS): Method and applications, Bone., 104, 66, 10.1016/j.bone.2017.01.035 McCloskey, 2015, Adjusting fracture probability by trabecular bone score, Calcif Tissue Int., 96, 500, 10.1007/s00223-015-9980-x Camacho, 2016, American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis — 2016, Endocr Pract., 22, 1, 10.4158/EP161435.GL Kanis, 2013, European guidance for the diagnosis and management of osteoporosis in postmenopausal women, Osteoporos Int., 24, 23, 10.1007/s00198-012-2074-y Hochberg, 2002, Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents, J Clin Endocrinol Metab., 87, 1586, 10.1210/jcem.87.4.8415 Bauer, 2016, Bisphosphonate-related changes in bone turnover are associated with vertebral, but not non-vertebral fracture risk reduction: A meta-regression, J Bone Miner Res., 31 Burch, 2014, Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: The secondary prevention of fractures, and primary prevention of fractures in high-risk groups, Health Technol Assess., 18, 1, 10.3310/hta18110 Gonzalez-Macias, 2015, Clinical practice guidelines for posmenopausal, glucocorticoid-induced and male osteoporosis. Spanish Society for Research on Bone and Mineral Metabolism (3rd updated version 2014), Rev Clin Esp., 215, 515 Vasikaran, 2011, Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: A need for international reference standards, Osteoporos Int., 22, 391, 10.1007/s00198-010-1501-1 Wall, 1997, Revised radiation doses for typical X-ray examinations. Report on a recent review of doses to patients from medical X-ray examinations in the UK by NRPB. National Radiological Protection Board, Br J Radiol., 70, 437, 10.1259/bjr.70.833.9227222 Adams, 2016, Opportunistic identification of vertebral fractures, J Clin Densitom., 19, 54, 10.1016/j.jocd.2015.08.010 Xu, 2011, Height loss, vertebral fractures, and the misclassification of osteoporosis, Bone., 48, 307, 10.1016/j.bone.2010.09.027 Siris, 2007, Enhanced prediction of fracture risk combining vertebral fracture status and BMD, Osteoporos Int., 18, 761, 10.1007/s00198-006-0306-8 Hallstrom, 2006, Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women, Osteoporos Int., 17, 1055, 10.1007/s00198-006-0109-y Giampietro, 2010, The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: A pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort, Osteoporos Int., 21, 467, 10.1007/s00198-009-0981-3 Kanis, 2005, Alcohol intake as a risk factor for fracture, Osteoporos Int., 16, 737, 10.1007/s00198-004-1734-y Choi, 2012, Effectiveness of intervention programs in preventing falls: A systematic review of recent 10 years and meta-analysis, J Am Med Dir Assoc., 13, 188.e13, 10.1016/j.jamda.2011.04.022 Goodwin, 2014, Multiple component interventions for preventing falls and fall-related injuries among older people: Systematic review and meta-analysis, BMC Geriatr., 14, 15, 10.1186/1471-2318-14-15 Tricco, 2017, Comparisons of interventions for preventing falls in older adults: A systematic review and meta-analysis, JAMA., 318, 1687, 10.1001/jama.2017.15006 Li, 2009, Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: A systematic review and meta-analysis, Clin Rehabil., 23, 888, 10.1177/0269215509339002 Santesso, 2014, Hip protectors for preventing hip fractures in older people, Cochrane Database Syst Rev., 10.1002/14651858.CD001255.pub5 Oliveira, 2016, Effects of whole body vibration on bone mineral density in postmenopausal women: A systematic review and meta-analysis, Osteoporos Int., 27, 2913, 10.1007/s00198-016-3618-3 Holick, 2011, Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline, J Clin Endocrinol Metab., 96, 1911, 10.1210/jc.2011-0385 Dawson-Hughes, 2010, IOF position statement: Vitamin D recommendations for older adults, Osteoporos Int., 21, 1151, 10.1007/s00198-010-1285-3 Haschka, 2015, Retro-study of reduction of therapy in patients with rheumatoid arthritis in ongoing remission, Ann Rheum Dis., 74, 668, 10.1136/annrheumdis-2015-eular.5961 Yazici, 2015, Routine assessment of patient index data 3 (RAPID3)-defined remission is as stringent as ACR/eular Boolean-defined remission in a clinical trial of patients with early rheumatoid arthritis treated with abatacept, Arthritis Rheumatol., 67 Harvey, 1988, Dose dependency of calcium absorption: A comparison of calcium carbonate and calcium citrate, J Bone Miner Res., 3, 253, 10.1002/jbmr.5650030303 Wallace, 2011, Urinary tract stone occurrence in the Women's Health Initiative (WHI) randomized clinical trial of calcium and vitamin D supplements, Am J Clin Nutr., 94, 270, 10.3945/ajcn.110.003350 Candelas, 2012, Calcium supplementation and kidney stone risk in osteoporosis: A systematic literature review, Clin Exp Rheumatol., 30, 954 Lewis, 2011, Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up, J Bone Miner Res., 26, 35, 10.1002/jbmr.176 Chung, 2016, Calcium intake and cardiovascular disease risk: An updated systematic review and meta-analysis, Ann Intern Med., 165, 856, 10.7326/M16-1165 Bolland, 2015, Calcium intake and risk of fracture: Systematic review, BMJ., 351, h4580, 10.1136/bmj.h4580 Moyer, 2013, Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med., 158, 691, 10.7326/0003-4819-158-6-201303190-00588 Bischoff-Ferrari, 2005, Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials, JAMA., 293, 2257, 10.1001/jama.293.18.2257 Avenell, 2014, Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men, Cochrane Database Syst Rev. Zhao, 2017, Association between calcium or vitamin D supplementation and fracture incidence in community-dwelling older adults: A systematic review and meta-analysis, JAMA., 318, 2466, 10.1001/jama.2017.19344 Weaver, 2016, Calcium plus vitamin D supplementation and risk of fractures: An updated meta-analysis from the National Osteoporosis Foundation, Osteoporos Int., 27, 367, 10.1007/s00198-015-3386-5 Michael, 2010, Primary care-relevant interventions to prevent falling in older adults: A systematic evidence review for the U.S. Preventive Services Task Force, Ann Intern Med., 153, 815, 10.7326/0003-4819-153-12-201012210-00008 Gillespie, 2009, Interventions for preventing falls in older people living in the community, Cochrane Database Syst Rev., 10.1002/14651858.CD007146.pub2 Uusi-Rasi, 2015, Exercise and vitamin D in fall prevention among older women: A randomized clinical trial, JAMA Intern Med., 175, 703, 10.1001/jamainternmed.2015.0225 Crandall, 2012 Wells, 2008, Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev. Wells, 2008, Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women, Cochrane Database Syst Rev. Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial, JAMA., 280, 2077, 10.1001/jama.280.24.2077 Harris, 1999, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial, JAMA, 282, 1344, 10.1001/jama.282.14.1344 Reginster, 2000, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis, Osteoporos Int, 11, 83, 10.1007/s001980050010 Black, 2007, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis, N Engl J Med., 356, 1809, 10.1056/NEJMoa067312 Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med., 361, 756, 10.1056/NEJMoa0809493 Neer, 2001, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med., 344, 1434, 10.1056/NEJM200105103441904 Chesnut, 2004, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis, J Bone Miner Res., 19, 1241, 10.1359/JBMR.040325 Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators, JAMA., 282, 637, 10.1001/jama.282.7.637 Silverman, 2008, Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial, J Bone Miner Res., 23, 1923, 10.1359/jbmr.080710 Lyles, 2007, Zoledronic acid and clinical fractures and mortality after hip fracture, N Engl J Med., 357, 1799, 10.1056/NEJMoa074941 McClung, 2001, Effect of risedronate on the risk of hip fracture in elderly women, N Engl J Med., 344, 333, 10.1056/NEJM200102013440503 Kendler, 2018, Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): A multicentre, double-blind, double-dummy, randomised controlled trial, Lancet., 391, 230, 10.1016/S0140-6736(17)32137-2 Marques, 2016, Cost-effectiveness of intervention thresholds for the treatment of osteoporosis based on FRAX® in Portugal, Calcif Tissue Int., 99, 131, 10.1007/s00223-016-0132-8 Lippuner, 2012, Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland, Osteoporos Int., 23, 2579, 10.1007/s00198-011-1869-6 Makras, 2015, Cost-effective osteoporosis treatment thresholds in Greece, Osteoporos Int., 26, 1949, 10.1007/s00198-015-3055-8 Dell, 2012, Incidence of atypical nontraumatic diaphyseal fractures of the femur, J Bone Miner Res., 27, 2544, 10.1002/jbmr.1719 Adler, 2016, Managing osteoporosis in patients on long-term bisphosphonate treatment: Report of a Task Force of the American Society for Bone and Mineral Research, J Bone Miner Res., 31, 16, 10.1002/jbmr.2708 Lo, 2010, Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure, J Oral Maxillofac Surg., 68, 243, 10.1016/j.joms.2009.03.050 McClung, 2017, Observations following discontinuation of long-term denosumab therapy, Osteoporos Int., 28, 1723, 10.1007/s00198-017-3919-1 Kaufman, 2005, Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy, Osteoporos Int., 16, 510, 10.1007/s00198-004-1713-3 Cosman, 2017, Treatment sequence matters: Anabolic and antiresorptive therapy for osteoporosis, J Bone Miner Res., 32, 198, 10.1002/jbmr.3051 Cosman, 2014, Anabolic and antiresorptive therapy for osteoporosis: Combination and sequential approaches, Curr Osteoporos Rep., 12, 385, 10.1007/s11914-014-0237-9 Leder, 2015, Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial, Lancet., 386, 1147, 10.1016/S0140-6736(15)61120-5 Ebina, 2017, The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis, J Bone Miner Metab., 35, 91, 10.1007/s00774-015-0731-x Obermayer-Pietsch, 2008, Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment, J Bone Miner Res., 23, 1591, 10.1359/jbmr.080506 Eiken, 2016, Treatment of osteoporosis after alendronate or risedronate, Osteoporos Int., 27, 1, 10.1007/s00198-015-3334-4 Anastasilakis, 2015, Denosumab in treatment-naive and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers, Metabolism., 64, 1291, 10.1016/j.metabol.2015.06.018 Cosman, 2011, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis, J Bone Miner Res., 26, 503, 10.1002/jbmr.238 Leder, 2014, Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The Data Extension Study): A randomized controlled trial, J Clin Endocrinol Metab., 99, 1694, 10.1210/jc.2013-4440 Inderjeeth, 2012, Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments, J Bone Miner Metab., 30, 493, 10.1007/s00774-012-0349-1 Black, 2000, Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial, J Clin Endocrinol Metab., 85, 4118, 10.1210/jcem.85.11.6953 Black, 2012, The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res., 27, 243, 10.1002/jbmr.1494 Ensrud, 2004, Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension, J Bone Miner Res., 19, 1259, 10.1359/JBMR.040326 Cummings, 2017, J Bone Miner Res., 32, 3, 10.1002/jbmr.3039 Black, 2006, Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial, JAMA., 296, 2927, 10.1001/jama.296.24.2927 Bone HG. Late-Breaking Abstract Presentations. Ten Years of Denosumab Treatment in Postmenopausal Women With Osteoporosis: Results From the FREEDOM Extension Trial. Presented at: American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting; Oct. 9-12, 2015; Seattle. Ferrari S, Adami S, Brown JP, Cosman F, Czerwinski E, de Gregorio LH, et al. Relationship Between Total Hip (TH) BMD T-score and Incidence of Nonvertebral Fracture (NVFX) With up to 10 Years of Denosumab (DMAb) Treatment. Presented at: European Calcified Tissue Society (ECTS) 2016 Annual Meeting: May 14-17, 2016; Rome. Siris, 2005, Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study, J Bone Miner Res., 20, 1514, 10.1359/JBMR.050509 Bauer, 2014, Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: The FLEX study, JAMA Intern Med., 174, 1126, 10.1001/jamainternmed.2014.1232 Black, 2015, The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT), J Bone Miner Res., 30, 934, 10.1002/jbmr.2442 Cosman, 2014, Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: When is it reasonable to discontinue treatment?, J Clin Endocrinol Metab., 99, 4546, 10.1210/jc.2014-1971 Moro Alvarez, 2016, Therapeutic holidays in osteoporosis: Long-term strategy of treatment with bisphosphonates, Med Clin (Barc)., 146, 24 Compston, 2013, Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013, Maturitas., 75, 392, 10.1016/j.maturitas.2013.05.013 Anagnostis, 2017, Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement, Maturitas., 101, 23, 10.1016/j.maturitas.2017.04.008 Tsourdi, 2017, Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS, Bone., 105, 11, 10.1016/j.bone.2017.08.003 Leder, 2009, Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis, J Clin Endocrinol Metab., 94, 2915, 10.1210/jc.2008-2630 Anastasilakis, 2017, Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: Systematic review and additional cases, J Bone Miner Res., 32, 1291, 10.1002/jbmr.3110 Weycker, 2006, Compliance with drug therapy for postmenopausal osteoporosis, Osteoporos Int., 17, 1645, 10.1007/s00198-006-0179-x Huybrechts, 2006, Assessment of compliance with osteoporosis treatment and its consequences in a managed care population, Bone., 38, 922, 10.1016/j.bone.2005.10.022 Bianchi, 2015, Improving adherence to and persistence with oral therapy of osteoporosis, Osteoporos Int., 26, 1629, 10.1007/s00198-015-3038-9 Hiligsmann, 2013, Interventions to improve osteoporosis medication adherence and persistence: A systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group, Osteoporos Int., 24, 2907, 10.1007/s00198-013-2364-z Eekman, 2014, Optimizing fracture prevention: The fracture liaison service, an observational study, Osteoporos Int., 25, 701, 10.1007/s00198-013-2481-8 Naranjo, 2015, Two-year adherence to treatment and associated factors in a fracture liaison service in Spain, Osteoporos Int., 26, 2579, 10.1007/s00198-015-3185-z Diez-Perez, 2017, Recommendations for the screening of adherence to oral bisphosphonates, Osteoporos Int., 28, 767, 10.1007/s00198-017-3906-6 Delmas, 2007, Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis, J Clin Endocrinol Metab., 92, 1296, 10.1210/jc.2006-1526 Eastell, 2003, Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate, J Bone Miner Res., 18, 1051, 10.1359/jbmr.2003.18.6.1051 Combs, 2013, “Due” for a scan: Examining the utility of monitoring densitometry, JAMA Intern Med., 173, 2007, 10.1001/jamainternmed.2013.8998 Buttgereit, 2015, Efficacy and safety of PF-04171327, a novel dissociated agonist of the glucocorticoid receptor (DAGR): Results of a phase 2, randomized, double-blind study, Ann Rheum Dis., 74, 737, 10.1136/annrheumdis-2015-eular.4897 Qaseem, 2017, Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians, Ann Intern Med., 166, 818, 10.7326/M15-1361 Sun, 2015, The effect of IL-6 neutralizing agents on depressed mood and anhedonia in immunology and oncology clinical, Neuropsychopharmacology., 40, S181 Diez-Perez, 2012, Treatment failure in osteoporosis, Osteoporos Int., 23, 2769, 10.1007/s00198-012-2093-8 Senn, 2014, Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: A 2-year open-label study, Osteoporos Int., 25, 1945, 10.1007/s00198-014-2703-8 Crandall, 2014, Comparative effectiveness of pharmacologic treatments to prevent fractures: An updated systematic review, Ann Intern Med., 161, 711, 10.7326/M14-0317 Kim, 2015, Bisphosphonates and risk of cardiovascular events: A meta-analysis, PLoS One., 10, e0122646, 10.1371/journal.pone.0122646 Wright, 2015, Bisphosphonates and evidence for association with esophageal and gastric cancer: A systematic review and meta-analysis, BMJ Open., 5, e007133, 10.1136/bmjopen-2014-007133 Arboleya, 2011, Adverse effects of bisphosphonates, Reumatol Clin., 7, 189, 10.1016/j.reuma.2010.10.005 Silva-Fernandez, 2013, Denosumab for the treatment of osteoporosis: A systematic literature review, Reumatol Clin., 9, 42, 10.1016/j.reuma.2012.06.007 Watts, 2012, Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: Coincidence or causal association?, Osteoporos Int., 23, 327, 10.1007/s00198-011-1755-2 Bagan, 2016, Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis, Oral Diseases., 22, 324, 10.1111/odi.12447 De Oliveira, 2016, Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) — Review, Med Oral Patol Oral Cir Bucal., 21, e431 Chamizo, 2013, Revisión sistemática de la literatura sobre la osteonecrosis maxilar con el uso de bisfosfonatos en pacientes con osteoporosis, Reumatol Clin., 9, 172, 10.1016/j.reuma.2012.05.005 Khan, 2015, Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus, J Bone Miner Res., 30, 3, 10.1002/jbmr.2405 Enciso, 2016, Assessing the utility of serum C-telopeptide cross-link of type 1 collagen as a predictor of bisphosphonate-related osteonecrosis of the jaw: A systematic review and meta-analysis, J Am Dent Assoc., 147, 551, 10.1016/j.adaj.2016.02.011 Hellstein, 2011, Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs, J Am Dent Assoc., 142, 1243, 10.14219/jada.archive.2011.0108 European Medicines Agency: prolia (denosumab). Disponible en: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/001120/WC500093526.pdf Shane, 2014, Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res., 29, 1, 10.1002/jbmr.1998 Lee, 2015, Increased risk for atypical fractures associated with bisphosphonate use, Fam Pract., 32, 276, 10.1093/fampra/cmu088 Gedmintas, 2013, Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis, J Bone Miner Res., 28, 1729, 10.1002/jbmr.1893 Liu, 2015, Association between alendronate and atypical femur fractures: A meta-analysis, Endocr Connect., 4, 58, 10.1530/EC-14-0120 Miller, 2016, Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates, J Clin Endocrinol Metab., 101, 3163, 10.1210/jc.2016-1801 Bianchi, 2012, Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension, Osteoporos Int., 23, 1769, 10.1007/s00198-011-1793-9 Pazianas, 2012, Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: A register-based cohort study using the US MarketScan claims databases, Osteoporos Int., 23, 2873, 10.1007/s00198-012-1952-7 Geada, 2014, [Atypical femoral fractures and bisphosphonates treatment: Is it a risk factor?], Acta Med Port., 27, 704, 10.20344/amp.5118 Bone, 2017, 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension, Lancet Diabetes Endocrinol., 5, 513, 10.1016/S2213-8587(17)30138-9 Sugimoto, 2014, Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: Results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT), Osteoporos Int., 26, 765, 10.1007/s00198-014-2964-2 Silverman, 2015, Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: Interim results from a prospective observational study, Osteoporos Int., 26, 361, 10.1007/s00198-014-2871-6 Watts, 2017, Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates, J Bone Miner Res., 32, 1027, 10.1002/jbmr.3081 Lems, 2017, EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures, Ann Rheum Dis., 76, 802, 10.1136/annrheumdis-2016-210289 Ganda, 2013, Models of care for the secondary prevention of osteoporotic fractures: A systematic review and meta-analysis, Osteoporos Int., 24, 393, 10.1007/s00198-012-2090-y McLellan, 2011, Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: A cost-effectiveness evaluation based on data collected over 8 years of service provision, Osteoporos Int., 22, 2083, 10.1007/s00198-011-1534-0 Fink, 2003, Disability after clinical fracture in postmenopausal women with low bone density: The fracture intervention trial (FIT), Osteoporos Int., 14, 69, 10.1007/s00198-002-1314-y Bonner, 2003, Health professional's guide to rehabilitation of the patient with osteoporosis, Osteoporos Int., 14, S1, 10.1007/s00198-002-1308-9 Newman, 2016, Spinal orthoses for vertebral osteoporosis and osteoporotic vertebral fracture: A systematic review, Arch Phys Med Rehabil., 97, 1013, 10.1016/j.apmr.2015.10.108 Solberg, 2016, Medial branch nerve block and ablation as a novel approach to pain related to vertebral compression fracture, Curr Opin Anaesthesiol., 29, 596, 10.1097/ACO.0000000000000375 Kendler, 2016, Vertebral fractures: Clinical importance and management, Am J Med., 129, 221.e1-10, 10.1016/j.amjmed.2015.09.020 Stevenson, 2014, Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for the treatment of osteoporotic vertebral fractures: A systematic review and cost-effectiveness analysis, Health Technol Assess., 18, 1, 10.3310/hta18170 Buchbinder, 2015, Percutaneous vertebroplasty for osteoporotic vertebral compression fracture, Cochrane Database Syst Rev., 10.1002/14651858.CD006349.pub2 Rodriguez, 2017, Pain, quality of life, and safety outcomes of kyphoplasty for vertebral compression fractures: Report of a Task Force of the American Society for Bone and Mineral Research, J Bone Miner Res., 32, 1935, 10.1002/jbmr.3170 Whittier, 2016, Glucocorticoid-induced osteoporosis, Rheum Dis Clin North Am., 42, 177, 10.1016/j.rdc.2015.08.005 Van Staa, 2003, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy, Arthritis Rheum., 48, 3224, 10.1002/art.11283 Allen, 2016, Bisphosphonates for steroid-induced osteoporosis, Cochrane Database Syst Rev., 10 Geusens, 2018, Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: The VERO Trial, J Bone Miner Res., 33, 783, 10.1002/jbmr.3384 Saag, 2007, Teriparatide or alendronate in glucocorticoid-induced osteoporosis, N Engl J Med., 357, 2028, 10.1056/NEJMoa071408 Saag, 2018, Denosumab versus risedronate in glucocorticoid-induced osteoporosis: A multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study, Lancet Diabetes Endocrinol., 6, 445, 10.1016/S2213-8587(18)30075-5 Gough, 1994, Generalised bone loss in patients with early rheumatoid arthritis, Lancet., 344, 23, 10.1016/S0140-6736(94)91049-9 Cooper, 1995, Rheumatoid arthritis, corticosteroid therapy and hip fracture, Ann Rheum Dis., 54, 49, 10.1136/ard.54.1.49 Chen, 2016, Increased risk of vertebral fracture in patients with rheumatoid arthritis: A meta-analysis, Medicine (Baltimore)., 95, e5262, 10.1097/MD.0000000000005262 Xue, 2017, Bone fracture risk in patients with rheumatoid arthritis: A meta-analysis, Medicine (Baltimore)., 96, e6983, 10.1097/MD.0000000000006983 Pray, 2017, Bone mineral density and fracture risk in ankylosing spondylitis: A meta-analysis, Calcif Tissue Int., 101, 182, 10.1007/s00223-017-0274-3 Wang, 2016, Fracture risk and bone mineral density levels in patients with systemic lupus erythematosus: A systematic review and meta-analysis, Osteoporos Int., 27, 1413, 10.1007/s00198-015-3449-7 Ramirez, 2018, Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis, Semin Arthritis Rheum., 48, 44, 10.1016/j.semarthrit.2017.12.001 Ogdie, 2017, The risk of fracture among patients with psoriatic arthritis and psoriasis: A population-based study, Ann Rheum Dis., 76, 882, 10.1136/annrheumdis-2016-210441 Mosca, 2010, European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies, Ann Rheum Dis., 69, 1269, 10.1136/ard.2009.117200 Roubille, 2015, Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: Expert opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative, J Rheumatol., 42, 1767, 10.3899/jrheum.141112 Loza, 2015, Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis, Rheumatol Int., 35, 445, 10.1007/s00296-014-3196-7 Curtis, 2015, Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab, Arthritis Rheumatol., 67, 1456, 10.1002/art.39075 Jain, 2016, Are men at high risk for osteoporosis underscreened? A quality improvement project, Perm J., 20, 60, 10.7812/TPP/14-190 Ebeling, 2013, Osteoporosis in men, Curr Opin Rheumatol., 25, 542, 10.1097/BOR.0b013e328362164d Watts, 2012, Osteoporosis in men: En Endocrine Society clinical practice guideline, J Clin Endocrinol Metab., 97, 1802, 10.1210/jc.2011-3045 Johnell, 2005, Predictive value of BMD for hip and other fractures, J Bone Miner Res., 20, 1185, 10.1359/JBMR.050304 Kanis, 2011, Towards a diagnostic and therapeutic consensus in male osteoporosis, Osteoporos Int., 22, 2789, 10.1007/s00198-011-1632-z Xu, 2017, Alendronate for the treatment of osteoporosis in men: A meta-analysis of randomized controlled trials, Am J Ther., 24, e130, 10.1097/MJT.0000000000000446 Zhong, 2009, Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials, Clin Drug Investig., 29, 349, 10.2165/00044011-200929050-00007 Orwoll, 2010, Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study, J Bone Miner Res., 25, 2239, 10.1002/jbmr.119 Niimi, 2015, Analysis of daily teriparatide treatment for osteoporosis in men, Osteoporos Int., 26, 1303, 10.1007/s00198-014-3001-1 Orwoll, 2003, The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis, J Bone Miner Res., 18, 9, 10.1359/jbmr.2003.18.1.9 Langdahl, 2015, A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: Results from the ADAMO trial, J Clin Endocrinol Metab., 100, 1335, 10.1210/jc.2014-4079 Lewiecki, 2008, International Society for Clinical Densitometry 2007 adult and pediatric official positions, bone., 43, 1115, 10.1016/j.bone.2008.08.106 Cohen, 2017, Premenopausal osteoporosis, Endocrinol Metab Clin North Am., 46, 117, 10.1016/j.ecl.2016.09.007 Peris Bernal, 2010, Osteoporosis in young individuals, Reumatol Clin., 6, 217, 10.1016/j.reuma.2009.01.014 McNicholl, 2010, The safety of bisphosphonate use in pre-menopausal women on corticosteroids, Curr Drug Saf., 5, 182, 10.2174/157488610790936178 FDA. Ficha técnica de FORTEO® [consultado 3 Dic 2017]. Disponible en: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021318s015lbl.pdf Torres, 2005, [How to slow down parathyroid hormone (PTH) secretion without the risk of inducing an adynamic bone disease], Nephrol Ther., 1, S337 Ketteler, 2017, Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: What's changed and why it matters, Kidney Int., 92, 26, 10.1016/j.kint.2017.04.006 Schipper, 2015, Treatment of osteoporosis in renal insufficiency, Clin Rheumatol., 34, 1341, 10.1007/s10067-015-2883-4 Miller, 2005, Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: A pooled analysis of nine clinical trials, J Bone Miner Res., 20, 2105, 10.1359/JBMR.050817 Ishani, 2008, The effect of raloxifene treatment in postmenopausal women with CKD, J Am Soc Nephrol., 19, 1430, 10.1681/ASN.2007050555 Melamed, 2011, Raloxifene, a selective estrogen receptor modulator, is renoprotective: A post-hoc analysis, Kidney Int., 79, 241, 10.1038/ki.2010.378 Jamal, 2011, Effects of denosumab on fracture and bone mineral density by level of kidney function, J Bone Miner Res., 26, 1829, 10.1002/jbmr.403 Guanabens, 2013, Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis, Hepatology., 58, 2070, 10.1002/hep.26466 Melek, 2014, Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: A meta-analysis and systematic review, Clin Gastroenterol Hepatol., 12, 32, 10.1016/j.cgh.2013.08.024 Cosman, 2016, Romosozumab treatment in postmenopausal women with osteoporosis, N Engl J Med., 375, 1532, 10.1056/NEJMoa1607948 Saag, 2017, Romosozumab or alendronate for fracture prevention in women with osteoporosis, N Engl J Med., 377, 1417, 10.1056/NEJMoa1708322 Miller, 2016, Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial, JAMA., 316, 722, 10.1001/jama.2016.11136